Candidate Aids vaccine passes key early test, Europe News & Top Stories

Maricruz Casares
Julio 9, 2018

Over the past 30 years, only four vaccines have been good enough to get into large scale human trials.

"However, it's important to be cautious and be clear that there's a lot of work to do before an effective HIV vaccine is readily available".

Based on the results from phase 1 and phase 2a clinical trials that involved almost 400 healthy adults in Rwanda, South Africa, Thailand, Uganda and the United States, a phase 2b trial has been initiated in southern Africa to determine the safety and efficacy of the HIV-1 vaccine candidate in 2,600 women at risk for acquiring HIV.

A key hurdle to HIV vaccine development has been the lack of direct comparability between clinical trials and preclinical studies.

Meant to provide broad protection from the many strains of HIV that are prevalent worldwide, the "mosaic" vaccine contains a patchwork of genetic sequences found among various HIV strains.

Dr Brady added that in the meantime there were already tools that were effective for preventing the disease from spreading, such as contraception and treatments for HIV-positive people that prevent them from passing on the virus. Through this study, the researchers have found a new vaccine that seems to be appropriate and safe and induces an immune in human beings as well as the rhesus monkeys. At this level, the vaccine proved to be capable of protecting the participants from the deadly virus.

More news: Iran's oil minister has hit back at Trump over production demands

A new study has given the researchers a ray of light in the battle to safeguard people from the most widespread virus, HIV-1.

All the new vaccine combinations showed to be safe, and produced the anti HIV response. Moreover, the vaccine candidate protected against infection with an HIV-like virus in monkeys.

For the experiment, the researchers recruited 393 healthy (non-HIV infected) adults ranging in age from 18 to 50 from 12 clinics in East Africa, South Africa, Thailand, and the United States. However, creating a vaccine has proven very hard for scientists "because there are so many strains of the virus" and " because HIV is adept at mutating to elude attack from our immune systems".

"We're cautiously optimistic but we need to be cautious in our interpretation of the data", Barouch told Newsweek.

It has been estimated that about 37 million people worldwide live with HIV or Aids, and there are an estimated 1.8 million new cases every year. "We have to acknowledge that developing an HIV vaccine is an unprecedented challenge, and we will not know for sure whether this vaccine will protect humans". They received 4 vaccinations through a period of forty-eight weeks. All vaccine regimens were well-tolerated and induced robust immune responses in the participants. It's unclear whether it would provide protection in humans.

"Implementation of even a moderately effective HIV vaccine together with the existing HIV prevention and treatment strategies is expected to contribute greatly to the evolving HIV/AIDS response", the editorial continued.

Otros informes por

Discuta este artículo

SIGUE NUESTRO PERIÓDICO